April 12, 2022
Japan will apply a new “zero” premium coefficient rule for the first time for two new medicines to be listed later this month, argenx’s Vyvgart (efgartigimod alfa) and Idorsia’s Pivlaz (clazosentan), with their cost disclosure ratios falling below 50%, Jiho...read more